ENTERAL PHARMACEUTICAL PREPARATION

Abstract: The invention discloses an enteral pharmaceutical preparation, which include black cumin oil (nigella sativa). The preparation may further includes dietary polyunsaturated fatty acids, such as flax oil (oleum lini).

Description: Enteral pharmaceutical preparation. FIELD OF INVENTION The present invention relates to an enteral pharmaceutical preparation. BACKGROUND TO INVENTION Many people all over the world suffer from the condition known as psoriasis. The skin of human beings is constantly being renewed. Thereby, as fast as dead cells in the outermost skin layer or epidermis are shed, they are being replaced by cells from the base of the epidermis. Psoriasis takes place when this procedure of replacement becomes "unbalanced", that is when the production of new cells increases while the shedding of dead cells remains normal. This has as consequence that the live cells accumulate and produce sections of inflamed, thickened skin covered by scales. Some persons suffer from extensive affected skin areas, which is unpleasant to view and causes discomfort. Various creams, ointments, injections and UV light treatments are known for treating psoriasis. However, there is no complete cure for psoriasis and none of the treatments appear to have any lasting effects on the vast majority of sufferers, and many of the remedies cause undesirable side effects. Even though the condition of psoriasis has been medically identified for more than 100 years, no satisfactory treatment or cure has been found. Worldwide, more and more people develop psoriatic symptoms, with the highest rate of increase observed in the "developed industrialised" world. It is an object of the invention to suggest a novel enteral pharmaceutical preparation for treatment of psoriasis, as well as other dermatological disorders. SUMMARY OF INVENTION According to the invention, an enteral pharmaceutical preparation includes black cumin oil (nigella sativa). The preparation may further include dietary polyunsaturated fatty acids. The dietary polyunsaturated fatty acids may include flax oil (oleum lini). Also according to the invention, an enteral pharmaceutical preparation includes a mixture of black cumin oil (nigella sativa) and flax oil (oleum lini). The black cumin oil (nigella sativa) and the flax oil (oleum lini) may be provided in a proportion by mass of about 1 :3. The black cumin oil (nigella sativa) and the flax oil (oleum lini) may be provided in a proportion by mass of about 1:1. The flax oil may be cold pressed unfiltered. The black cumin oil may be cold pressed. The preparation may include vegetable oils rich in alpha-linolenic (Omega 3) essential fatty acids. The preparation may include vegetable oils rich in alpha-linoleic (Omega 6) essential fatty acids. The preparation may include essential vitamins and minerals. The preparation may include the following (in percentage by mass): a) Fatty acids: Omega 3 (Linolenic) 40.1 % Omega 6 (Linoleic) 29.2 % Oleic 18.8 % Palmitic 6.7 % Stearic 3.3 % Myristic 0.1 % Palmitoleic 0.1 % Arachidic 0.2 % Gadoleic 0.2 % Other fatty acids 0.7 % Total fatty acids 99.4 % b) Aromatic Oils: P-Cymene 0.25 % Thymo-Hydrochinone 0.21 % Alpha-Pinene 0.09 % Other Aromatic Oils 0.05 % Total Aromatic Oils 0.60 % Total Oil Content: 100.00 % The preparation may be used for treatment of psoriasis, arthritis, high cholesterol disorders or gout disorders. Also according to the invention, a method of treating psoriasis in affected persons, includes the steps of enteral administration of an effective quantity of an enteral pharmaceutical preparation including black cumin oil (nigella sativa). Yet further according to the invention, a method of treating psoriasis in affected persons includes the steps of enteral administration of an effective quantity of an enternal pharmaceutical preparation including a mixure of black cumin oil (nigella sativa) and flax oil (oleum lini). The enteral pharmaceutical preparation may further include dietary polyunsaturated acids. The dietary polyunsaturated acids may include flax oil (oleum lini). DESCRIPTION OF PREFERRED EXAMPLES Example 1 In this example the pharmaceutical preparation in accordance with the invention includes flax oil and black cumin oil. The constitutents of this pharmaceutical preparation are as follows (in percentage by mass): Summary: Total polyunsat. 75.3% Mono-unsaturates 16.4 % Saturates 8.3 % Total 100.0 % In the above the flax oil and Black-Cumin oil respectively are composed as follows: Black-Cumin Oil: a) Fattv Acid Composition: Myristic 0.2 % Palmitic 12.4 % Palmitoleic 0.2 % Stearic 2.7 % Oleic 23.7 % Omega 6 (Linoleic) 57.2 % Omega 3 (Linolenic) 0.2 % Arachidic 0.4 % Gadoleic 0.4 % Other 0.6 % Total fatty acids 98.0 % b) Aromatic Oil Composition: Alpha Terpinene 0,018 % P-Cymene 0,750 % Carvone 0,008 % Thymo-Hydrochinene 0,618 % Alpha-Pinene 0,272 % Beta-Pinene 0,104 % Limonene 0,070 % Others 0,160 % Total Aromatic Oils 2,0 % Flax oil: Omega 3 (Linolenic) 60.1 % Omega 6 (Linoleic) 15.2 % Oleic 16.4 % Palmitic 3.9 % Stearic 3.6 % Other 0.8 % Total 100.0 % From the above it can be seen that the total fatty acids constitute up to 98 % of the black-cumin oil, and aromatic oils total 2 % by mass respectively. In one example of treatment, the dosage involved a total of two tablespoons (a total of 20 ml) per day, preferably at breakfast, but in stubborn cases of psoriasis, an initial dose of three to four tablespoons (30 to 40 ml per day) may be required. The preparation preferably is used as follows: Adults: 2 tablespoons (20 ml) per day Children: 3 to 5 years: 1 teaspoon (5 ml) per day 6 to 10 years: 2 teaspoons (10 ml) per day 10 to 16 years: 3 teaspoons (15 ml) per day with breakfast. Taste may be a problem and the oil can be mixed into juices or other carrier substances. It has been found that black-cumin oil may lead to an increased appetite. Where the oral intake of oils is disliked, it is advised to mix the pharmceutical preparation in accordance with the invention into salads and yoghurt or other suitable carrier dishes. In the case of patients suffering from diabetes it must be noted that black-cumin oil may lead to low blood sugar (hypoglycaemia), and such a patient's insulin requirements may have to be adjusted accordingly. For this reason diabetes patients have to remain under strict medical supervision until the effects of the pharmaceutical preparation on blood sugar levels have been reliably established. Example 2 In this example in summary the following is included (in percentage by mass): Total poly-unsaturated fatty acids 69.3 % Total mono-unsaturated fatty acids 18.8 % Saturated fatty acids 11.3 % Total aromatic oils 0.6 % Total 100.0 % Of the above groupings the compositions are (in percentage by mass): a) Fatty acids: Omega 3 (Linolenic) 40.1 % Omega 6 (Linoleic) 29.2 % Oleic 18.8 % Palmitic 6.7 % Stearic 3.3 % Myristic 0.1 % Palmitoleic 0.1 % Arachidic 0.2 % Gadoleic 0.2 % Other 0.7 % Total fatty acids 99.4 % b) Aromatic Oils: P-Cymene 0.25 % Thymo-Hydrochinone 0.21 % Alpha-Pinene 0.09 % Other 0.05 % Total aromatic oils 0.60 % Sum Total: 100.00 % The other aromatic oils (sum total 0.05 %) included: Carvone, Beta-Pinene, Limonene, Behemic Acid, Sabinene, 1 ,8-Cinchole, Artemisia-Ketone, Linalool, Beta-Thujone, Bornyl-Acetate, Carvacrole, Thymole, and others. In traces the following are provided: Vitamins: B1 , B2, B6, Folic Acid, Niacine. Minerals: Iron, Calcium, Magnesium, Zinc, Selenium Various Amino Acids and Enzymes. The preparation preferably is used as follows: Adults: 2 tablespoons ("large spoon") children: 3 to 5 years: 1 teaspoon 6 to 10 years: 2 teaspoons 10 to 16 years: 3 teaspoons per day with breakfast. First improvements are normally noticed after three to four weeks, sometimes sooner, sometimes later. 90 % of patients fall within the 3 to 4 weeks category. The healing process must first commence, after which the "thick skin" will slowly peel off, displaying new pinkish skin areas. The pink colour is due to the fact that new skin must first develop melanin. The process of healing and regeneration will require several months, varying from individual to individual. Optimum levels of improvement will be reached after approximately 6 months, sometimes sooner, sometimes later.

Claims: CLAIMS 1. An enteral pharmaceutical preparation, which includes black cumin oil (nigella sativa). 2. A preparation as claimed in claim 1 , which further includes dietary polyunsaturated fatty acids. 3. A preparation as claimed in claim 2, in which the dietary polyunsaturated fatty acids include flax oil (oleum lini). 4. An enteral pharmaceutical preparation, which includes a mixture of black cumin oil (nigella sativa) and flax oil (oleum lini). 5. A preparation as claimed in claim 4, in which the black cumin oil (nigella sativa) and the flax oil (oleum lini) are provided in a proportion by mass of about 1 :3. 6. A preparation as claimed in claim 4, in which the black cumin oil (nigella sativa) and the flax oil (oleum lini) are provided in a proportion by mass of about 1 :1. 7. A preparation as claimed in any one of claims 3 to 6, in which the flax oil is cold pressed unfiltered. 8. A preparation as claimed in any one of the preceding claims, in which the black cumin oil is cold pressed. 9. A preparation as claimed in any one of the preceding claims, which includes vegetable oils rich in alpha-linolenic (Omega 3) essential fatty acids. 10. A preparation as claimed in any one of the preceding claims, which includes vegetable oils rich in alpha-linoleic (Omega 6) essential fatty acids. 11. A preparation as claimed in any one of the preceding claims, which includes essential vitamins and minerals. 12. A preparation as claimed in any one of claims 3 to 11 , which includes (in percentage by mass): a) Fattv acids: Omega 3 (Linolenic)40.1 % Omega 6 (Linoleic)29.2 % Oleic 18.8 % Palmitic 6.7 % Stearic 3.3 % Myristic 0.1 % Palmitoleic 0.1 % Arachidic 0.2 % Gadoleic 0.2 % Other fatty acids 0.7 % Total fatty acids 99.4 % b) Aromatic Oils P-Cymene 0.25 % Thymo-Hydrochinone 0.21 % Alpha-Pinene 0.09 % Other Aromatic Oils 0.05 % Total Aromatic Oils 0.60 % Total Oil Content: 100.00 % 13. A preparation as claimed in any one of the preceding claims, which is to be used for treatment of psoriasis. 14. A preparation as claimed in any one of claims 1 to 12, which is to be used for treatment of arthritis. 15. A preparation as claimed in any one of claims 1 to 12, which is to be used for treatment of high cholesterol disorders. 16. A preparation as claimed in any one of claims 1 to 12, which is to be used for treatment of gout disorders. 17. A method of treating psoriasis in affected persons, which includes the steps of entemal administration of an effective quantity of an enternal pharmaceutical preparation including black cumin oil (nigella sativa). 18. A method of treating psoriasis in affected persons, which includes the steps of enteral administration of an effective quantity of an enternal pharmaceutical preparation including a mixure of black cumin oil (nigella sativa) and flax oil (oleum lini). 19. A method as claimed in claim 17 or claim 18, in which the enteral pharmaceutical preparation further includes dietary polyunsaturated fatty acids. 20. A method as claimed in claim 19, in which the dietary polyunsaturated fatty acids include flax oil (oleum lini).

Inventors: CREDE HELFRIED HANS RUDOLF, CREDE, HELFRIED, HANS, RUDOLF
Applicants: CREDE HELFRIED HANS RUDOLF, CREDE THOMAS, CREDE, HELFRIED, HANS, RUDOLF, CREDE, THOMAS
Application year: 1999
Main classification: A61K35
IPC codes: A61K36, A61P17